On November 23, 2017, National Pharmaceutical Pricing Authority (NPPA) has fixed/revised the retail price/ceiling price of 51 formulations of schedule-I formulations under Drug Price Control Order (DPCO), 2013. However, the price capping of the existing schedule I formulations / new drugs formulations is exclusive of goods and services tax applicable, if any. The updates on ceiling/retail prices capping are discussed point wise –
1. NPPA, by its first notification, has fixed the ceiling prices of six formulations including prices of Japanese Encephalitis and measles rubella vaccines exclusive of goods and services tax, if any. The price fixing is performed in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 15, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013 for below formulations-
2. NPPA, by its second notification, has revised the ceiling prices of eight scheduled formulations after suppressing its previous notifications SO 2060(E) & S.O. 2061(E) dated June 30, 2017 as listed in the table –
3. NPPA, by its third notification has fixed the ceiling prices of below seven formulations on the basis of procurement prices; and in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013 which makes it mandatory to fix ceiling prices of scheduled formulations –
4. NPPA, by its fourth notification, has revised the ceiling prices of below seven formulations by suppressing its notification no. S. O. 2060(E) and SO 2061(E) dated June 30, 2017, and in exercise of the powers conferred by paragraphs 19 of the Drugs (Prices Control) Order, 2013 as it is necessary to fix ceiling prices of scheduled formulations –
5. NPPA fixed the retail price of New Drug formulations applicable only to the individual manufacturers / marketers who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013. For example – the retail price of each film coated tablet of Sofosbuvir & Velpatasvir has been fixed, which contains: Sofosbuvir 400mg and Velpatasvir 100mg is supplied by six odd combinations of manufacturer & marketing companies i.e. M/s Hetero Labs Ltd. is a manufacturer and M/s Abbott India Ltd is a marketing company1.
6. NPPA has further notified the retail price of new Drug formulations applicable only to the individual manufacturers / marketers who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 as mentioned below-
7. NPPA fixed the retail price of 1 scheduled formulation (Volitra Enzo enteric coated tablet) in implementation of review orders issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013.
Volitra Enzo enteric coated tablet which contains: Trypsin 48mg Bromelain 90mg Rutoside Trihydrate 100mg Diclofenac Sodium 50mg manufactured by M/s Akums Drugs & Pharmaceuticals Ltd. and marketed by M/s Sun Pharmaceuticals Ind. Ltd2.
8. NPPA fixed the retail price of two formulations in implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013. Hereby NPPA revise the retail price of Ceftriaxone Powder for Injection 1gm each pack and Chloroquine Tablet 150mg per tablet3.
Footnotes
1 http://www.nppaindia.nic.in/ceiling/press23oct17/Prices(5).pdf
2 http://www.nppaindia.nic.in/ceiling/press23oct17/Prices(7).pdf
3 http://www.nppaindia.nic.in/ceiling/press23oct17/Prices(8).pdf
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
